Chiron Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Chiron Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$9.93M	Buy	+64,843	New	+$7.66M	1.38%	42

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chiron Investment Management's CRSP Position: Q4 2020 in Review

Chiron Investment Management opened a new position in CRISPR Therapeutics (CRSP) in Q4 2020: 64,843 shares worth $9.93M. The stake represents 1.38% of the portfolio and ranks #42 among its holdings.

412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

Chiron Investment Management held 64,843 shares of CRISPR Therapeutics worth $9.93M as of Q4 2020.
CRISPR Therapeutics was a new Chiron Investment Management position in Q4 2020.
CRISPR Therapeutics made up 1.38% of Chiron Investment Management's portfolio in Q4 2020, its #42 holding.
412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Chiron Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.